Leveraging Data Fusion Strategies in Multireceptor Lead Optimization MM/GBSA End-Point Methods.
暂无分享,去创建一个
Robert Abel | Richard A. Friesner | Jennifer L. Knight | Goran Krilov | Joshua Williams | John R. Gunn | Kenneth W. Borrelli | Alec Clowes | Luciano Cheng | R. Friesner | K. Borrelli | J. Gunn | Robert Abel | Goran Krilov | Joshua Williams | Luciano Cheng | A. Clowes
[1] Jean-Michel Rondeau,et al. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides. , 2012, Journal of medicinal chemistry.
[2] W. Sherman,et al. Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field. , 2010, Journal of chemical theory and computation.
[3] M. Gilson,et al. Free energy, entropy, and induced fit in host-guest recognition: calculations with the second-generation mining minima algorithm. , 2004, Journal of the American Chemical Society.
[4] Johan Åqvist,et al. Ligand binding affinity prediction by linear interaction energy methods , 1998, J. Comput. Aided Mol. Des..
[5] Ronald M. Levy,et al. PrimeX and the Schrödinger computational chemistry suite of programs , 2012 .
[6] Gabriela Chiosis,et al. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. , 2006, Journal of medicinal chemistry.
[7] Dariusz Plewczynski,et al. Brainstorming: weighted voting prediction of inhibitors for protein targets , 2010, Journal of molecular modeling.
[8] Gabriela Chiosis,et al. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. , 2005, Journal of medicinal chemistry.
[9] T. Halgren. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions , 1996 .
[10] Yuzhu Chen,et al. N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. , 2004, Journal of medicinal chemistry.
[11] Lawrence C Kuo,et al. 3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6. , 2006, Bioorganic & medicinal chemistry letters.
[12] Philip J. Merta,et al. Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.
[13] W. L. Jorgensen,et al. General model for estimation of the inhibition of protein kinases using Monte Carlo simulations. , 2004, Journal of medicinal chemistry.
[14] Chang Park,et al. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. , 2007, Journal of medicinal chemistry.
[15] B. Berne,et al. Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. , 2008, Journal of the American Chemical Society.
[16] G Narahari Sastry,et al. Virtual high throughput screening in new lead identification. , 2011, Combinatorial chemistry & high throughput screening.
[17] Jacob Kongsted,et al. An improved method to predict the entropy term with the MM/PBSA approach , 2009, J. Comput. Aided Mol. Des..
[18] Chang Park,et al. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[19] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[20] Pallav D. Patel,et al. Paralog-selective Hsp 90 inhibitors define tumor-specific regulation of Her 2 , 2014 .
[21] Christine Humblet,et al. Chemical space sampling by different scoring functions and crystal structures , 2010, J. Comput. Aided Mol. Des..
[22] Youwei Yan,et al. Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides. , 2003, Bioorganic & medicinal chemistry letters.
[23] Lawrence C Kuo,et al. Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position. , 2003, Bioorganic & medicinal chemistry letters.
[24] Youwei Yan,et al. Design and synthesis of potent and selective macrocyclic thrombin inhibitors. , 2003, Bioorganic & medicinal chemistry letters.
[25] Tingjun Hou,et al. Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..
[26] Young Do Kwon,et al. Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. , 2011, Bioorganic & medicinal chemistry.
[27] B. Honig,et al. A hierarchical approach to all‐atom protein loop prediction , 2004, Proteins.
[28] Ludmila I. Kuncheva,et al. Measures of Diversity in Classifier Ensembles and Their Relationship with the Ensemble Accuracy , 2003, Machine Learning.
[29] Wei Chen,et al. Modeling Protein-Ligand Binding by Mining Minima. , 2010, Journal of chemical theory and computation.
[30] A. Moretto,et al. Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site. , 2007, Journal of medicinal chemistry.
[31] Chao-Yie Yang,et al. Importance of ligand reorganization free energy in protein-ligand binding-affinity prediction. , 2009, Journal of the American Chemical Society.
[32] Peter Willett,et al. Combination of Similarity Rankings Using Data Fusion , 2013, J. Chem. Inf. Model..
[33] Thomas A. Halgren,et al. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular. interactions , 1996, J. Comput. Chem..
[34] G. Narahari Sastry,et al. Molecular Dynamics Investigation on a Series of HIV Protease Inhibitors: Assessing the Performance of MM-PBSA and MM-GBSA Approaches , 2012, J. Chem. Inf. Model..
[35] R. Wexler,et al. Chapter 9. Anticoagulants: Thrombin and Factor Xa Inhibitors , 1999 .
[36] Miklos Feher,et al. Consensus scoring for protein-ligand interactions. , 2006, Drug discovery today.
[37] J. Fleiss. Measuring nominal scale agreement among many raters. , 1971 .
[38] M. Gilson,et al. Calculation of protein-ligand binding affinities. , 2007, Annual review of biophysics and biomolecular structure.
[39] Clive McCarthy,et al. Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.
[40] Jens Carlsson,et al. Charges for Large Scale Binding Free Energy Calculations with the Linear Interaction Energy Method. , 2009, Journal of chemical theory and computation.
[41] Gisbert Schneider,et al. Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.
[42] W. L. Jorgensen,et al. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.
[43] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[44] Fredrik Svensson,et al. Virtual Screening Data Fusion Using Both Structure- and Ligand-Based Methods , 2012, J. Chem. Inf. Model..
[45] Woody Sherman,et al. Exploring protein flexibility: incorporating structural ensembles from crystal structures and simulation into virtual screening protocols. , 2012, The journal of physical chemistry. B.
[46] Philip J. Merta,et al. 1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: extended exploration on phenyl ring substitutions and preliminary ADME/PK studies. , 2007, Bioorganic & medicinal chemistry letters.
[47] Wei Li,et al. Structure‐Based Optimization of Protein Tyrosine Phosphatase‐1 B Inhibitors: Capturing Interactions with Arginine 24 , 2008, ChemMedChem.
[48] Robert Abel,et al. Motifs for molecular recognition exploiting hydrophobic enclosure in protein–ligand binding , 2007, Proceedings of the National Academy of Sciences.
[49] Christine Humblet,et al. Investigation of MM-PBSA Rescoring of Docking Poses , 2008, J. Chem. Inf. Model..
[50] Kenneth L. Ho,et al. Significant reduction in errors associated with nonbonded contacts in protein crystal structures: automated all-atom refinement with PrimeX , 2012, Acta crystallographica. Section D, Biological crystallography.
[51] Woody Sherman,et al. Generation of Receptor Structural Ensembles for Virtual Screening Using Binding Site Shape Analysis and Clustering , 2012, Chemical biology & drug design.
[52] R. Friesner,et al. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .
[53] J. Åqvist,et al. The linear interaction energy method for predicting ligand binding free energies. , 2001, Combinatorial chemistry & high throughput screening.
[54] Simona Distinto,et al. How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information , 2009, J. Chem. Inf. Model..
[55] Daniel R McMasters,et al. Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines. , 2003, Journal of medicinal chemistry.
[56] P. Kollman,et al. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .
[57] M. Noble,et al. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination. , 2006, Journal of the American Chemical Society.
[58] A. Osnowski,et al. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. , 2004, Journal of medicinal chemistry.
[59] B. Kuhn,et al. Validation and use of the MM-PBSA approach for drug discovery. , 2005, Journal of medicinal chemistry.
[60] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[61] Pallav D. Patel,et al. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. , 2013, Nature chemical biology.
[62] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[63] Kai Zhu,et al. Improved Methods for Side Chain and Loop Predictions via the Protein Local Optimization Program: Variable Dielectric Model for Implicitly Improving the Treatment of Polarization Effects. , 2007, Journal of chemical theory and computation.
[64] A. Ortiz,et al. Assessment of solvation effects on calculated binding affinity differences: trypsin inhibition by flavonoids as a model system for congeneric series. , 1997, Journal of medicinal chemistry.
[65] Suresh Babu,et al. Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction. , 2012, ACS medicinal chemistry letters.
[66] ANATOLY M. RUVINSKY. Role of binding entropy in the refinement of protein–ligand docking predictions: Analysis based on the use of 11 scoring functions , 2007, J. Comput. Chem..
[67] Lawrence C Kuo,et al. Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors. , 2004, Journal of medicinal chemistry.
[68] Woody Sherman,et al. Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors , 2012, Journal of Computer-Aided Molecular Design.
[69] Josef Kittler,et al. Combining classifiers: A theoretical framework , 1998, Pattern Analysis and Applications.
[70] T. Halgren. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular‐interaction energies and geometries , 1999, Journal of computational chemistry.
[71] Chang Park,et al. Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors. , 2007, Journal of medicinal chemistry.
[72] Woody Sherman,et al. Rapid Shape-Based Ligand Alignment and Virtual Screening Method Based on Atom/Feature-Pair Similarities and Volume Overlap Scoring , 2011, J. Chem. Inf. Model..
[73] P. Kollman,et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.
[74] S. Noha,et al. Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques , 2011, Bioorganic & medicinal chemistry letters.
[75] Alessandro Contini,et al. Explicit Ligand Hydration Shells Improve the Correlation between MM-PB/GBSA Binding Energies and Experimental Activities. , 2013, Journal of chemical theory and computation.
[76] Christian Kramer,et al. MM/GBSA Binding Energy Prediction on the PDBbind Data Set: Successes, Failures, and Directions for Further Improvement , 2013, J. Chem. Inf. Model..
[77] Woody Sherman,et al. ConfGen: A Conformational Search Method for Efficient Generation of Bioactive Conformers , 2010, J. Chem. Inf. Model..
[78] Julian Tirado-Rives,et al. Improving MM-GB/SA Scoring through the Application of the Variable Dielectric Model. , 2011, Journal of chemical theory and computation.
[79] Z. Xiang,et al. On the role of the crystal environment in determining protein side-chain conformations. , 2002, Journal of molecular biology.
[80] Woody Sherman,et al. Boosting Virtual Screening Enrichments with Data Fusion: Coalescing Hits from Two-Dimensional Fingerprints, Shape, and Docking , 2013, J. Chem. Inf. Model..
[81] Victor Guallar,et al. Exploring hierarchical refinement techniques for induced fit docking with protein and ligand flexibility , 2009, J. Comput. Chem..
[82] Giulio Rastelli,et al. Fast and accurate predictions of binding free energies using MM‐PBSA and MM‐GBSA , 2009, J. Comput. Chem..
[83] B. Graves,et al. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors , 2011, Journal of medicinal chemistry.
[84] R. Friesner,et al. The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling , 2011, Proteins.
[85] Anatoly M. Ruvinsky,et al. New and fast statistical‐thermodynamic method for computation of protein‐ligand binding entropy substantially improves docking accuracy , 2005, J. Comput. Chem..
[86] Woody Sherman,et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.
[87] William Greenlee,et al. Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation. , 2012, Journal of medicinal chemistry.
[88] Daniel Hoffmann,et al. The Normal-Mode Entropy in the MM/GBSA Method: Effect of System Truncation, Buffer Region, and Dielectric Constant , 2012, J. Chem. Inf. Model..
[89] J. Aqvist,et al. A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.